NEW YORK – Enzo Biochem reported after the close of the market on Monday that revenues for its fiscal third quarter fell 14 percent year over year, as the COVID-19 pandemic adversely affected its clinical services revenues, diagnostic testing volumes, and product revenues.
For the three months ended April 30, the diagnostics company reported total revenues of $16.9 million compared to $19.7 million in the year-ago quarter.